Back to top
more

Xencor (XNCR)

(Real Time Quote from BATS)

$15.48 USD

15.48
1,073,453

-0.22 (-1.40%)

Updated Aug 8, 2024 09:40 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Xencor (XNCR) Beats Q1 Earnings and Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of 155.71% and 302.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Pacira's (PCRX) Q1 Earnings Miss Estimates, Revenues Rise Y/Y

Pacira's (PCRX) earnings fall shy of estimates in the first quarter of 2022 while revenues beat the same.

United Therapeutics (UTHR) Q1 Earnings & Sales Beat, Stock Up

United Therapeutics' (UTHR) first-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.

Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates

Zoetis' (ZTS) earnings and revenues trump estimates in the first quarter of 2022.

JAZZ Q1 Earnings Miss, Sales Robust, 2022 Guidance Raised

JAZZ's product revenues grow in the first quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals. It raises guidance on strong results.

Sarepta (SRPT) Q1 Earnings Beat, DMD Drugs' Sales Robust

Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the first quarter. Stock up in after-market trading.

Tirthankar Chakraborty headshot

3 Best Profitable Stocks to Buy Using Net Income Ratio

Xencor (XNCR), Encore Wire (WIRE) & Silvergate Capital (SI) have been selected as the top profitable picks with a high net income ratio.

Esperion (ESPR) Q1 Earnings Beat on Robust Demand for Drugs

Esperion Therapeutics (ESPR) reports solid first-quarter results, beating estimates for earnings and sales. Cost-savings programs boost margins. Stock rallies.

Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Lags Revenue Estimates

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 0.96% and 66.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Q4 Earnings and Revenues Beat Estimates

Xencor (XNCR) delivered earnings and revenue surprises of 157.45% and 42.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Teladoc's (TDOC) Q4 Earnings?

Teladoc Health's (TDOC) Q4 results are expected to gain from high sales and visits volume.

Xencor (XNCR) to Report Q4 Results: Wall Street Expects Earnings Growth

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of 8.00% and 11.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Arena (ARNA) Q3 Loss Wider Than Anticipated, Revenues Nil

Arena Pharmaceuticals (ARNA) misses Q3 bottom-line estimates. The company progresses with pipeline development.

Aerie's (AERI) Q3 Earnings Miss Estimates, Revenues Rise Y/Y

Aerie (AERI) incurs wider-than-expected loss in the third quarter of 2021 while sales match expectations.

Ironwood (IRWD) Q3 Earnings Top, Sales Hurt by Lower Price

Ironwood (IRWD) witnesses flat year-over-year sales as growth in demand for Linzess gets partially offset by lower net price of the drug. The company maintains revenue guidance. Stock down.

United Therapeutics (UTHR) Q3 Earnings & Sales Beat, Stock Up

United Therapeutics (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.

Agios (AGIO) Reports Narrower-Than-Expected Loss in Q3

Agios Pharmaceuticals (AGIO) posts narrower-than-expected loss for the third quarter of 2021. It does not record any revenues in the quarter.

Esperion (ESPR) Beats on Q3 Earnings, Lowers Expense Guidance

Esperion Therapeutics (ESPR) reports solid third-quarter results, beating estimates for earnings and sales. However, the stock declines in pre-market trading.

Earnings Preview: Xencor (XNCR) Q3 Earnings Expected to Decline

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Industry Outlook Highlights: Xencor, Enanta, Catalyst Pharmaceuticals, and Molecular Templates

Zacks Industry Outlook Highlights: Xencor, Enanta, Catalyst Pharmaceuticals, and Molecular Templates

Can Xencor (XNCR) Climb 48% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 48.1% upside potential for Xencor (XNCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Kinjel Shah headshot

4 Small Drug Stocks That Hold Promise Despite Industry Challenges

Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry players' third-quarter results. XNCR, ENTA, CPRX and MTEM may prove to be good additions to one's portfolio.

Entasis' (ETTX) Phase III Study on Infection Drug Meets Goal

Entasis' (ETTX) phase III ATTACK study achieves primary endpoint. The study evaluates its investigational combo drug SUL-DUR in infections caused by Acinetobacter baumannii.

United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised)

United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.